NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
Ocellaris Pharma, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
Fate Therapeutics
University of Texas Southwestern Medical Center
Royal Marsden NHS Foundation Trust
National Institutes of Health Clinical Center (CC)
University of Pittsburgh
PH Research, S.L.